Cargando…

PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers

BACKGROUND: The PEOPLE trial aimed to identify new immune biomarkers in negative and low programmed death-ligand 1 (PD-L1) (0%-49%) advanced non-small-cell lung cancer (aNSCLC) patients treated with first-line pembrolizumab. Here we report the main outcomes and the circulating immune biomarkers anal...

Descripción completa

Detalles Bibliográficos
Autores principales: Lo Russo, G., Sgambelluri, F., Prelaj, A., Galli, F., Manglaviti, S., Bottiglieri, A., Di Mauro, R.M., Ferrara, R., Galli, G., Signorelli, D., De Toma, A., Occhipinti, M., Brambilla, M., Rulli, E., Triulzi, T., Torelli, T., Agnelli, L., Brich, S., Martinetti, A., Dumitrascu, A.D., Torri, V., Pruneri, G., Fabbri, A., de Braud, F., Anichini, A., Proto, C., Ganzinelli, M., Mortarini, R., Garassino, M.C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808469/
https://www.ncbi.nlm.nih.gov/pubmed/36455507
http://dx.doi.org/10.1016/j.esmoop.2022.100645